Impact of Types of Lymphocyte Chromosomal Aberrations on Human Cancer Risk

Results from Nordic and Italian Cohorts

Lars Hagmar, Ulf Strömberg, Stefano Bonassi, Inger Lise Hansteen, Lisbeth Ehlert Knudsen, Carita Lindholm, Hannu Norppa

Research output: Contribution to journalArticle

194 Citations (Scopus)

Abstract

The frequency of cells with structural chromosomal aberrations (CAs) in peripheral blood lymphocytes is the first genotoxicity biomarker that has shown an association with cancer risk. CAs are usually divided into chromosome-type (CSAs) and chromatid-type aberrations (CTAs), with different mechanisms of formation. From a mechanistic point of view, it is of interest to clarify whether the cancer predictivity of CAs is different with respect to CSAs and CTAs. We report here cancer risk for cytogenetically tested, healthy subjects with respect to frequency of CAs, CSAs, and CTAs in peripheral blood lymphocytes, using Nordic (1981 subjects with CA data, 1871 subjects with CSA/CTA data) and Italian (1573 subjects with CA data, 877 subjects with CTA/ CSA data) cohorts, with a median follow-up of 17 years. High levels of CAs at test were clearly associated with increased total cancer incidence in the Nordic cohorts and increased total cancer mortality in the Italian cohort. In the Nordic cohorts, significantly elevated cancer risks were observed for subjects with both high CSAs and high CTAs at test, and these variables showed equally strong cancer predictivity. The results of the Italian cohort did not indicate any clear-cut difference in cancer predictivity between the CSA and CTA biomarkers. There was no significant effect modification by age at test, gender, country, or time since test. The results suggest that both DNA double-strand breaks and other initial DNA lesions responsible for CSAs and CTAs are associated with cancer risk.

Original languageEnglish
Pages (from-to)2258-2263
Number of pages6
JournalCancer Research
Volume64
Issue number6
DOIs
Publication statusPublished - Mar 15 2004

Fingerprint

Chromatids
Chromosome Aberrations
Lymphocytes
Neoplasms
Biomarkers
Double-Stranded DNA Breaks
Healthy Volunteers
Chromosomes
Mortality
DNA
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Impact of Types of Lymphocyte Chromosomal Aberrations on Human Cancer Risk : Results from Nordic and Italian Cohorts. / Hagmar, Lars; Strömberg, Ulf; Bonassi, Stefano; Hansteen, Inger Lise; Knudsen, Lisbeth Ehlert; Lindholm, Carita; Norppa, Hannu.

In: Cancer Research, Vol. 64, No. 6, 15.03.2004, p. 2258-2263.

Research output: Contribution to journalArticle

Hagmar, Lars ; Strömberg, Ulf ; Bonassi, Stefano ; Hansteen, Inger Lise ; Knudsen, Lisbeth Ehlert ; Lindholm, Carita ; Norppa, Hannu. / Impact of Types of Lymphocyte Chromosomal Aberrations on Human Cancer Risk : Results from Nordic and Italian Cohorts. In: Cancer Research. 2004 ; Vol. 64, No. 6. pp. 2258-2263.
@article{4a403e5df56f42a5b0c834963437f155,
title = "Impact of Types of Lymphocyte Chromosomal Aberrations on Human Cancer Risk: Results from Nordic and Italian Cohorts",
abstract = "The frequency of cells with structural chromosomal aberrations (CAs) in peripheral blood lymphocytes is the first genotoxicity biomarker that has shown an association with cancer risk. CAs are usually divided into chromosome-type (CSAs) and chromatid-type aberrations (CTAs), with different mechanisms of formation. From a mechanistic point of view, it is of interest to clarify whether the cancer predictivity of CAs is different with respect to CSAs and CTAs. We report here cancer risk for cytogenetically tested, healthy subjects with respect to frequency of CAs, CSAs, and CTAs in peripheral blood lymphocytes, using Nordic (1981 subjects with CA data, 1871 subjects with CSA/CTA data) and Italian (1573 subjects with CA data, 877 subjects with CTA/ CSA data) cohorts, with a median follow-up of 17 years. High levels of CAs at test were clearly associated with increased total cancer incidence in the Nordic cohorts and increased total cancer mortality in the Italian cohort. In the Nordic cohorts, significantly elevated cancer risks were observed for subjects with both high CSAs and high CTAs at test, and these variables showed equally strong cancer predictivity. The results of the Italian cohort did not indicate any clear-cut difference in cancer predictivity between the CSA and CTA biomarkers. There was no significant effect modification by age at test, gender, country, or time since test. The results suggest that both DNA double-strand breaks and other initial DNA lesions responsible for CSAs and CTAs are associated with cancer risk.",
author = "Lars Hagmar and Ulf Str{\"o}mberg and Stefano Bonassi and Hansteen, {Inger Lise} and Knudsen, {Lisbeth Ehlert} and Carita Lindholm and Hannu Norppa",
year = "2004",
month = "3",
day = "15",
doi = "10.1158/0008-5472.CAN-03-3360",
language = "English",
volume = "64",
pages = "2258--2263",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Impact of Types of Lymphocyte Chromosomal Aberrations on Human Cancer Risk

T2 - Results from Nordic and Italian Cohorts

AU - Hagmar, Lars

AU - Strömberg, Ulf

AU - Bonassi, Stefano

AU - Hansteen, Inger Lise

AU - Knudsen, Lisbeth Ehlert

AU - Lindholm, Carita

AU - Norppa, Hannu

PY - 2004/3/15

Y1 - 2004/3/15

N2 - The frequency of cells with structural chromosomal aberrations (CAs) in peripheral blood lymphocytes is the first genotoxicity biomarker that has shown an association with cancer risk. CAs are usually divided into chromosome-type (CSAs) and chromatid-type aberrations (CTAs), with different mechanisms of formation. From a mechanistic point of view, it is of interest to clarify whether the cancer predictivity of CAs is different with respect to CSAs and CTAs. We report here cancer risk for cytogenetically tested, healthy subjects with respect to frequency of CAs, CSAs, and CTAs in peripheral blood lymphocytes, using Nordic (1981 subjects with CA data, 1871 subjects with CSA/CTA data) and Italian (1573 subjects with CA data, 877 subjects with CTA/ CSA data) cohorts, with a median follow-up of 17 years. High levels of CAs at test were clearly associated with increased total cancer incidence in the Nordic cohorts and increased total cancer mortality in the Italian cohort. In the Nordic cohorts, significantly elevated cancer risks were observed for subjects with both high CSAs and high CTAs at test, and these variables showed equally strong cancer predictivity. The results of the Italian cohort did not indicate any clear-cut difference in cancer predictivity between the CSA and CTA biomarkers. There was no significant effect modification by age at test, gender, country, or time since test. The results suggest that both DNA double-strand breaks and other initial DNA lesions responsible for CSAs and CTAs are associated with cancer risk.

AB - The frequency of cells with structural chromosomal aberrations (CAs) in peripheral blood lymphocytes is the first genotoxicity biomarker that has shown an association with cancer risk. CAs are usually divided into chromosome-type (CSAs) and chromatid-type aberrations (CTAs), with different mechanisms of formation. From a mechanistic point of view, it is of interest to clarify whether the cancer predictivity of CAs is different with respect to CSAs and CTAs. We report here cancer risk for cytogenetically tested, healthy subjects with respect to frequency of CAs, CSAs, and CTAs in peripheral blood lymphocytes, using Nordic (1981 subjects with CA data, 1871 subjects with CSA/CTA data) and Italian (1573 subjects with CA data, 877 subjects with CTA/ CSA data) cohorts, with a median follow-up of 17 years. High levels of CAs at test were clearly associated with increased total cancer incidence in the Nordic cohorts and increased total cancer mortality in the Italian cohort. In the Nordic cohorts, significantly elevated cancer risks were observed for subjects with both high CSAs and high CTAs at test, and these variables showed equally strong cancer predictivity. The results of the Italian cohort did not indicate any clear-cut difference in cancer predictivity between the CSA and CTA biomarkers. There was no significant effect modification by age at test, gender, country, or time since test. The results suggest that both DNA double-strand breaks and other initial DNA lesions responsible for CSAs and CTAs are associated with cancer risk.

UR - http://www.scopus.com/inward/record.url?scp=1542720377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542720377&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-03-3360

DO - 10.1158/0008-5472.CAN-03-3360

M3 - Article

VL - 64

SP - 2258

EP - 2263

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 6

ER -